PDCD1 and melanoma: Coinhibition of anti–LAG-3+anti–PD-1 is more attractive than blocking either LAG-3 or PD-1 alone (8), with encouraging efficacy even in patients with anti–PD-1/anti–PD-L1–refractory melanoma (9, 10).